{"id":338631,"date":"2025-08-19T15:42:59","date_gmt":"2025-08-19T15:42:59","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/how-to-buy-vertex-pharmaceuticals-incorporated\/"},"modified":"2025-08-19T15:42:59","modified_gmt":"2025-08-19T15:42:59","slug":"how-to-buy-vertex-pharmaceuticals-incorporated","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-vertex-pharmaceuticals-incorporated\/","title":{"rendered":"Vertex Pharmaceuticals Incorporated (VRTX) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Vertex Pharmaceuticals Incorporated (VRTX) Hisse Senedi Yat\u0131r\u0131m\u0131"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334126,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-338631","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"Vertex Pharmaceuticals Incorporated (VRTX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Vertex Pharmaceuticals Incorporated (VRTX) Hisse Senedi Yat\u0131r\u0131m\u0131","h1_source":{"label":"H1","type":"text","formatted_value":"Vertex Pharmaceuticals Incorporated (VRTX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Vertex Pharmaceuticals Incorporated (VRTX) Hisse Senedi Yat\u0131r\u0131m\u0131"},"description":"Vertex Pharmaceuticals (VRTX) hisselerine nas\u0131l yat\u0131r\u0131m yap\u0131laca\u011f\u0131n\u0131, g\u00fcncel fiyat analizini, 2025 b\u00fcy\u00fcme kataliz\u00f6rlerini ve maksimum getiri i\u00e7in ad\u0131m ad\u0131m sat\u0131n alma talimatlar\u0131n\u0131 \u00f6\u011frenin.","description_source":{"label":"Description","type":"textarea","formatted_value":"Vertex Pharmaceuticals (VRTX) hisselerine nas\u0131l yat\u0131r\u0131m yap\u0131laca\u011f\u0131n\u0131, g\u00fcncel fiyat analizini, 2025 b\u00fcy\u00fcme kataliz\u00f6rlerini ve maksimum getiri i\u00e7in ad\u0131m ad\u0131m sat\u0131n alma talimatlar\u0131n\u0131 \u00f6\u011frenin."},"intro":"Genetik t\u0131bb\u0131 devrim niteli\u011finde de\u011fi\u015ftiren bir biyoteknoloji devi \u00fczerine yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Vertex Pharmaceuticals (VRTX) sadece ba\u015fka bir biyoteknoloji hissesi de\u011fil\u2014kistik fibrozisi \u00f6l\u00fcmc\u00fcl bir hastal\u0131ktan y\u00f6netilebilir bir duruma d\u00f6n\u00fc\u015ft\u00fcren \u015firket. \u00c7\u0131\u011f\u0131r a\u00e7an CRISPR terapileri ve geni\u015fleyen \u00fcr\u00fcn hatt\u0131 ile VRTX, yerle\u015fik gelir ve patlay\u0131c\u0131 b\u00fcy\u00fcme potansiyelinin m\u00fckemmel birle\u015fimini sunuyor. Bu hissenin neden dikkatinizi hak etti\u011fine ve bug\u00fcn nas\u0131l hissedar olabilece\u011finize birlikte bakal\u0131m.","intro_source":{"label":"Intro","type":"text","formatted_value":"Genetik t\u0131bb\u0131 devrim niteli\u011finde de\u011fi\u015ftiren bir biyoteknoloji devi \u00fczerine yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Vertex Pharmaceuticals (VRTX) sadece ba\u015fka bir biyoteknoloji hissesi de\u011fil\u2014kistik fibrozisi \u00f6l\u00fcmc\u00fcl bir hastal\u0131ktan y\u00f6netilebilir bir duruma d\u00f6n\u00fc\u015ft\u00fcren \u015firket. \u00c7\u0131\u011f\u0131r a\u00e7an CRISPR terapileri ve geni\u015fleyen \u00fcr\u00fcn hatt\u0131 ile VRTX, yerle\u015fik gelir ve patlay\u0131c\u0131 b\u00fcy\u00fcme potansiyelinin m\u00fckemmel birle\u015fimini sunuyor. Bu hissenin neden dikkatinizi hak etti\u011fine ve bug\u00fcn nas\u0131l hissedar olabilece\u011finize birlikte bakal\u0131m."},"body_html":"<h2>\ud83d\udcc8 G\u00fcncel Hisse Fiyat\u0131 ve Piyasa Konumu<\/h2> <p>19 A\u011fustos 2025 itibar\u0131yla, Vertex Pharmaceuticals (VRTX) NASDAQ borsas\u0131nda <strong>389,88 $<\/strong> seviyesinde i\u015flem g\u00f6r\u00fcyor. Hisse senedi son alt\u0131 ayda \u00f6nemli dalgalanmalar ya\u015fad\u0131 ve \u015fu anda Kas\u0131m 2024'te ula\u015f\u0131lan 519,88 $'l\u0131k t\u00fcm zamanlar\u0131n en y\u00fcksek seviyesinin yakla\u015f\u0131k %25 alt\u0131nda bulunuyor.<\/p> <p><strong>\u00d6nemli Tarih Uyar\u0131s\u0131: 3 Kas\u0131m 2025<\/strong>, Vertex'in 2025 3. \u00e7eyrek kazan\u00e7 raporunu yay\u0131nlayaca\u011f\u0131 bir sonraki b\u00fcy\u00fck kataliz\u00f6r olarak i\u015faretleniyor. Tarihsel veriler bu t\u00fcr olaylar\u0131n hisse fiyat\u0131n\u0131 dramatik \u015fekilde hareket ettirdi\u011fini g\u00f6steriyor\u2014son olarak 4 A\u011fustos'taki kazan\u00e7 raporu g\u00fc\u00e7l\u00fc finansal sonu\u00e7lara ra\u011fmen hisse senedinde dalgalanmalara yol a\u00e7t\u0131.<\/p> <h3>Kazan\u00e7lar\u0131n Etki Analizi:<\/h3> <ul> <li>4 A\u011fustos 2025: 4,52 $ d\u00fczeltilmi\u015f hisse ba\u015f\u0131 kazan\u00e7 (EPS) bildirdi (4,24 $ tahminini ge\u00e7ti) ve 2,96 milyar $ gelir (2,89 milyar $ tahminini ge\u00e7ti)<\/li> <li>May\u0131s 2025: Gelir art\u0131\u015f\u0131na ra\u011fmen 1. \u00e7eyrek kazan\u00e7 beklentisi %5,44 ka\u00e7\u0131r\u0131ld\u0131 (4,06 $ vs 4,29 $ beklenen)<\/li> <li>\u015eubat 2025: Kistik fibrozis tedavisindeki geni\u015fleme ile g\u00fc\u00e7l\u00fc kazan\u00e7<\/li> <li>Kas\u0131m 2024: \u00dcr\u00fcn hatt\u0131 g\u00fcncellemeleri ile sa\u011flam performans<\/li> <li>A\u011fustos 2024: Baz\u0131 \u00fcr\u00fcn hatt\u0131 aksakl\u0131klar\u0131 ile kar\u0131\u015f\u0131k sonu\u00e7lar<\/li> <li>May\u0131s 2024: Uluslararas\u0131 geni\u015flemeden g\u00fc\u00e7l\u00fc b\u00fcy\u00fcme<\/li> <\/ul> <p>Model, Vertex'in zaman zaman k\u0131sa vadeli beklentileri ka\u00e7\u0131rsa da uzun vadeli e\u011filimin g\u00fc\u00e7l\u00fc \u015fekilde pozitif oldu\u011funu ve kazan\u00e7 s\u00fcrprizlerinin \u00e7o\u011funun olumlu y\u00f6nde ger\u00e7ekle\u015fti\u011fini ortaya koyuyor.<\/p> <h3>6 Ayl\u0131k Fiyat Seyri (\u015eubat-A\u011fustos 2025)<\/h3> <p>Vertex hisseleri zorlu ama nihayetinde \u00f6d\u00fcllendirici bir yol izledi:<\/p> <ul> <li><strong>\u015eubat 2025<\/strong>: 415-425 $ aral\u0131\u011f\u0131 (4. \u00e7eyrek kazan\u00e7 sonras\u0131 iyimserlik)<\/li> <li><strong>Mart 2025<\/strong>: 390-400 $ (genel piyasa d\u00fczeltmesi)<\/li> <li><strong>Nisan 2025<\/strong>: 375-385 $ (1. \u00e7eyrek kazan\u00e7 hayal k\u0131r\u0131kl\u0131\u011f\u0131)<\/li> <li><strong>May\u0131s 2025<\/strong>: 365-375 $ (sekt\u00f6r genelinde biyoteknoloji sat\u0131\u015flar\u0131)<\/li> <li><strong>Haziran 2025<\/strong>: 380-390 $ (\u00fcr\u00fcn hatt\u0131 haberleriyle toparlanma)<\/li> <li><strong>Temmuz 2025<\/strong>: 395-405 $ (NHS England ALYFTREK anla\u015fmas\u0131 ile destek)<\/li> <li><strong>A\u011fustos 2025<\/strong>: 385-395 $ (mevcut i\u015flem aral\u0131\u011f\u0131)<\/li> <\/ul> <p>Dalgalanmalara ra\u011fmen, hisse senedi her d\u00fc\u015f\u00fc\u015ften sonra \u00f6nemli bir diren\u00e7 g\u00f6sterdi; yat\u0131r\u0131mc\u0131lar Vertex'in franchise i\u015finin ve yenilik\u00e7i \u00fcr\u00fcn hatt\u0131n\u0131n temel de\u011ferini fark ediyor.<\/p> [cta_green text=\"Ticarete Ba\u015fla\"]<h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2> <p><strong>2025 Y\u0131l Sonu Hedefi<\/strong>: 440-460 $<br> ALYFTREK benimsenmesi ve Casgevy geni\u015flemesinden kaynaklanan b\u00fcy\u00fcmenin 3. ve 4. \u00e7eyrek kazan\u00e7lar\u0131nda devam etmesi, ayr\u0131ca a\u011fr\u0131 ve diyabet programlar\u0131ndan potansiyel olumlu veriler bekleniyor.<\/p> <p><strong>2026 Projeksiyonu<\/strong>: 480-520 $<br> ALYFTREK'in yakla\u015f\u0131k 1 milyar $ sat\u0131\u015fa ula\u015fmas\u0131, Casgevy'nin potansiyel olarak blockbuster olmas\u0131 (1 milyar $+), ve \u00fcr\u00fcn hatt\u0131ndan yeni lansmanlar.<\/p> <p><strong>2028 G\u00f6r\u00fcn\u00fcm\u00fc<\/strong>: 580-650 $<br> Opioid olmayan a\u011fr\u0131 tedavilerinin tam ticarile\u015fmesi, tip 1 diyabet tedavi pazar\u0131na giri\u015f ve geni\u015fletilmi\u015f gen terapisi uygulamalar\u0131.<\/p> <p><strong>2030 Vizyonu<\/strong>: 700-800 $+<br> Genetik t\u0131pta bask\u0131n konum, birden fazla hastal\u0131k i\u00e7in potansiyel k\u00fcratif tedaviler ve \u00e7e\u015fitli terap\u00f6tik alanlarda k\u00fcresel pazar liderli\u011fi.<\/p> <p><strong>Karar<\/strong>: Uzun vadeli yat\u0131r\u0131mc\u0131lar i\u00e7in G\u00dc\u00c7L\u00dc ALIM. Mevcut fiyat, birden fazla kataliz\u00f6r\u00fcn ger\u00e7ekle\u015fmesinden \u00f6nce cazip bir giri\u015f noktas\u0131 sunuyor.<\/p> <h2>\u26a0\ufe0f Yat\u0131r\u0131m Riskleri ve Olumlu \u0130\u015faretler<\/h2> <h3>Dikkate Al\u0131nmas\u0131 Gereken Riskler:<\/h3> <ul> <li><strong>Patent S\u00fcresi Dolmas\u0131<\/strong>: Ana patentlerin s\u00fcresinin dolmas\u0131na ba\u011fl\u0131 %35 gelir azalmas\u0131 riski<\/li> <li><strong>Reg\u00fclasyon Zorluklar\u0131<\/strong>: 250 milyon $'a kadar potansiyel para cezalar\u0131 ve onay gecikmeleri<\/li> <li><strong>Ar-Ge Ba\u015far\u0131s\u0131zl\u0131klar\u0131<\/strong>: Klinik denemelerde ba\u015far\u0131s\u0131zl\u0131k durumunda 500 milyon $+ risk<\/li> <li><strong>Yo\u011funla\u015fma Riski<\/strong>: Gelirin %99'unun kistik fibrozis tedavilerinden gelmesi nedeniyle k\u0131r\u0131lganl\u0131k<\/li> <li><strong>Klinik Geri Ad\u0131mlar<\/strong>: Solunan mRNA terapisi \u00fczerindeki son duraklama geli\u015fim risklerini g\u00f6steriyor<\/li> <\/ul> <h3>2025 \u0130\u00e7in Ye\u015fil I\u015f\u0131klar:<\/h3> <ul> <li><strong>ALYFTREK Ba\u015far\u0131s\u0131<\/strong>: Temmuz 2025'te NHS England geri \u00f6deme anla\u015fmas\u0131 sa\u011fland\u0131, eski tedavilere k\u0131yasla %71 etkinlik ile \u00fcst\u00fcn klinik sonu\u00e7lar<\/li> <li><strong>Casgevy Patlamas\u0131<\/strong>: 1. \u00e7eyrekte %77,5 ard\u0131\u015f\u0131k b\u00fcy\u00fcme ile 14,2 milyon $ sat\u0131\u015f, blockbuster stat\u00fcs\u00fcne do\u011fru ilerliyor<\/li> <li><strong>\u00dcr\u00fcn Hatt\u0131 \u0130lerlemesi<\/strong>: VX-880, Faz III denemelerinde %42 akci\u011fer fonksiyonu iyile\u015fmesi g\u00f6steriyor<\/li> <li><strong>Stratejik Sat\u0131n Almalar<\/strong>: 4,9 milyar $ Alpine Immune Sciences sat\u0131n al\u0131m\u0131, b\u00f6brek hastal\u0131klar\u0131 programlar\u0131n\u0131 h\u0131zland\u0131r\u0131yor<\/li> <li><strong>Sekt\u00f6r Tan\u0131n\u0131rl\u0131\u011f\u0131<\/strong>: 2025 TIME100 En Etkili \u015eirketler listesine se\u00e7ildi<\/li> <\/ul> <h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h2> <ol> <li><strong>K\u00fc\u00e7\u00fck Ba\u015flay\u0131n<\/strong>: Portf\u00f6y\u00fcn\u00fcz\u00fcn %2-5'ini temsil eden bir pozisyonla ba\u015flay\u0131n\u2014500 $ bile kesirli hisse al\u0131m\u0131 i\u00e7in yeterlidir<\/li> <li><strong>Dolar Maliyet Ortalamas\u0131<\/strong>: Dalgalanma s\u0131ras\u0131nda zamanlama hatalar\u0131n\u0131 \u00f6nlemek i\u00e7in ayl\u0131k sabit tutarlarda yat\u0131r\u0131m yap\u0131n<\/li> <li><strong>Fiyat Uyar\u0131lar\u0131 Kurun<\/strong>: 3 Kas\u0131m kazan\u00e7lar\u0131 civar\u0131nda potansiyel al\u0131m f\u0131rsatlar\u0131n\u0131 izleyin<\/li> <li><strong>Uzun Vadeli D\u00fc\u015f\u00fcn\u00fcn<\/strong>: Bu, 3-5 y\u0131ll\u0131k bir yat\u0131r\u0131m hikayesi, h\u0131zl\u0131 bir i\u015flem de\u011fil<\/li> <\/ol> <p>Esprili bir yorum: \"VRTX ticareti yapmak, bir CRISPR deneyini izlemek gibidir\u2014k\u0131sa vadede bazen karma\u015f\u0131k, ancak bilim i\u015fe yararsa devrim niteli\u011finde sonu\u00e7lar potansiyeli var!\"<\/p> <h2>\u2705 Vertex Pharmaceuticals Incorporated (VRTX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ad\u0131m Ad\u0131m<\/h2> <table border=\"1\" cellpadding=\"5\" cellspacing=\"0\"> <thead> <tr> <th>Ad\u0131m<\/th> <th>\u0130\u015flem<\/th> <th>Neden \u00d6nemli<\/th> <\/tr> <\/thead> <tbody> <tr> <td>1<\/td> <td>Bir Ticaret Platformu Se\u00e7in<\/td> <td>NASDAQ listeleri ve k\u00fc\u00e7\u00fck yat\u0131r\u0131mlar i\u00e7in kesirli hisse sunan platformlar\u0131 tercih edin<\/td> <\/tr> <tr> <td>2<\/td> <td>Hesap Fonlamas\u0131n\u0131 Tamamlay\u0131n<\/td> <td>Risk almaya haz\u0131r oldu\u011funuz bir miktarla ba\u015flay\u0131n\u2014100 $ bile yeterlidir<\/td> <\/tr> <tr> <td>3<\/td> <td>\"VRTX\" Aramas\u0131 Yap\u0131n<\/td> <td>Sadece \"Vertex\" de\u011fil, tam sembol\u00fc kullan\u0131n<\/td> <\/tr> <tr> <td>4<\/td> <td>Emir T\u00fcr\u00fcn\u00fc Se\u00e7in<\/td> <td>Giri\u015f fiyat\u0131n\u0131 kontrol etmek i\u00e7in limit emirleri kullan\u0131n; dalgalanma s\u0131ras\u0131nda piyasa emirlerinden ka\u00e7\u0131n\u0131n<\/td> <\/tr> <tr> <td>5<\/td> <td>\u0130nceleyin ve Onaylay\u0131n<\/td> <td>Komisyon \u00fccretlerini kontrol edin\u2014i\u015flem de\u011ferinizin %1'inden az olmas\u0131na dikkat edin<\/td> <\/tr> <\/tbody> <\/table> <h3>Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Pocket Option'\u0131n \u00d6ne \u00c7\u0131kma Nedenleri<\/h3> <p>Pocket Option, yeni ba\u015flayanlar i\u00e7in \u00f6zelliklerle hisse senedi yat\u0131r\u0131m\u0131n\u0131 devrim niteli\u011finde de\u011fi\u015ftiriyor:<\/p> <ul> <li><strong>5 $ Minimum Para Yat\u0131rma<\/strong>: Minimal riskle stratejileri test etmek i\u00e7in ideal<\/li> <li><strong>An\u0131nda Do\u011frulama<\/strong>: Tek belge ile KYC, dakikalar i\u00e7inde i\u015flem yapman\u0131z\u0131 sa\u011flar<\/li> <li><strong>\u00c7e\u015fitli Para \u00c7ekme Se\u00e7enekleri<\/strong>: Kripto, e-c\u00fczdanlar ve geleneksel bankac\u0131l\u0131k dahil 100'den fazla y\u00f6ntem<\/li> <li><strong>Kesirli Hisseler<\/strong>: VRTX gibi y\u00fcksek fiyatl\u0131 hisselere tam hisse almadan yat\u0131r\u0131m yapma imkan\u0131<\/li> <\/ul> <h2>\ud83c\udf0d 2025'te Vertex: Genetik T\u0131bb\u0131n \u00d6nc\u00fcs\u00fc<\/h2> <p>Vertex Pharmaceuticals, kistik fibrozis tedavi pazar\u0131nda %90'dan fazla paya sahip ancak bu sadece ba\u015flang\u0131\u00e7. \u015eirket, CRISPR ortakl\u0131\u011f\u0131 arac\u0131l\u0131\u011f\u0131yla gen d\u00fczenlemeye h\u0131zla geni\u015fliyor, orak h\u00fccre hastal\u0131\u011f\u0131, beta-talasemi ve potansiyel olarak tip 1 diyabet i\u00e7in tedavi geli\u015ftirmekte.<\/p> <p>Son <a href=\"https:\/\/www.thepharmaletter.com\/pharmaceutical\/vertex-secures-nhs-deal-for-once-daily-cystic-fibrosis-therapy\">NHS England ALYFTREK anla\u015fmas\u0131<\/a>, yeni nesil tedavilerinin ticari uygulanabilirli\u011fini g\u00f6sterirken, <a href=\"https:\/\/time.com\/collections\/time100-companies-2025\/7289665\/vertex-pharmaceuticals\/\">TIME100 tan\u0131n\u0131rl\u0131\u011f\u0131<\/a> ila\u00e7 geli\u015ftirmedeki yenilik\u00e7i yakla\u015f\u0131mlar\u0131n\u0131 do\u011fruluyor.<\/p> <p><strong>\u0130lgin\u00e7 Bilgi<\/strong>: Vertex'in ara\u015ft\u0131rma tesisinde, bilim insanlar\u0131n\u0131n ba\u015far\u0131s\u0131z deneyleri kutlad\u0131\u011f\u0131 \u00f6zel bir \"ba\u015far\u0131s\u0131zl\u0131k laboratuvar\u0131\" bulunuyor\u2014\u00e7\u00fcnk\u00fc her ba\u015far\u0131s\u0131zl\u0131k, genetik t\u0131pta ger\u00e7ekten i\u015fe yarayan\u0131 anlamalar\u0131na bir ad\u0131m daha yakla\u015ft\u0131r\u0131yor!<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 G\u00fcncel Hisse Fiyat\u0131 ve Piyasa Konumu<\/h2>\n<p>19 A\u011fustos 2025 itibar\u0131yla, Vertex Pharmaceuticals (VRTX) NASDAQ borsas\u0131nda <strong>389,88 $<\/strong> seviyesinde i\u015flem g\u00f6r\u00fcyor. Hisse senedi son alt\u0131 ayda \u00f6nemli dalgalanmalar ya\u015fad\u0131 ve \u015fu anda Kas\u0131m 2024&#8217;te ula\u015f\u0131lan 519,88 $&#8217;l\u0131k t\u00fcm zamanlar\u0131n en y\u00fcksek seviyesinin yakla\u015f\u0131k %25 alt\u0131nda bulunuyor.<\/p>\n<p><strong>\u00d6nemli Tarih Uyar\u0131s\u0131: 3 Kas\u0131m 2025<\/strong>, Vertex&#8217;in 2025 3. \u00e7eyrek kazan\u00e7 raporunu yay\u0131nlayaca\u011f\u0131 bir sonraki b\u00fcy\u00fck kataliz\u00f6r olarak i\u015faretleniyor. Tarihsel veriler bu t\u00fcr olaylar\u0131n hisse fiyat\u0131n\u0131 dramatik \u015fekilde hareket ettirdi\u011fini g\u00f6steriyor\u2014son olarak 4 A\u011fustos&#8217;taki kazan\u00e7 raporu g\u00fc\u00e7l\u00fc finansal sonu\u00e7lara ra\u011fmen hisse senedinde dalgalanmalara yol a\u00e7t\u0131.<\/p>\n<h3>Kazan\u00e7lar\u0131n Etki Analizi:<\/h3>\n<ul>\n<li>4 A\u011fustos 2025: 4,52 $ d\u00fczeltilmi\u015f hisse ba\u015f\u0131 kazan\u00e7 (EPS) bildirdi (4,24 $ tahminini ge\u00e7ti) ve 2,96 milyar $ gelir (2,89 milyar $ tahminini ge\u00e7ti)<\/li>\n<li>May\u0131s 2025: Gelir art\u0131\u015f\u0131na ra\u011fmen 1. \u00e7eyrek kazan\u00e7 beklentisi %5,44 ka\u00e7\u0131r\u0131ld\u0131 (4,06 $ vs 4,29 $ beklenen)<\/li>\n<li>\u015eubat 2025: Kistik fibrozis tedavisindeki geni\u015fleme ile g\u00fc\u00e7l\u00fc kazan\u00e7<\/li>\n<li>Kas\u0131m 2024: \u00dcr\u00fcn hatt\u0131 g\u00fcncellemeleri ile sa\u011flam performans<\/li>\n<li>A\u011fustos 2024: Baz\u0131 \u00fcr\u00fcn hatt\u0131 aksakl\u0131klar\u0131 ile kar\u0131\u015f\u0131k sonu\u00e7lar<\/li>\n<li>May\u0131s 2024: Uluslararas\u0131 geni\u015flemeden g\u00fc\u00e7l\u00fc b\u00fcy\u00fcme<\/li>\n<\/ul>\n<p>Model, Vertex&#8217;in zaman zaman k\u0131sa vadeli beklentileri ka\u00e7\u0131rsa da uzun vadeli e\u011filimin g\u00fc\u00e7l\u00fc \u015fekilde pozitif oldu\u011funu ve kazan\u00e7 s\u00fcrprizlerinin \u00e7o\u011funun olumlu y\u00f6nde ger\u00e7ekle\u015fti\u011fini ortaya koyuyor.<\/p>\n<h3>6 Ayl\u0131k Fiyat Seyri (\u015eubat-A\u011fustos 2025)<\/h3>\n<p>Vertex hisseleri zorlu ama nihayetinde \u00f6d\u00fcllendirici bir yol izledi:<\/p>\n<ul>\n<li><strong>\u015eubat 2025<\/strong>: 415-425 $ aral\u0131\u011f\u0131 (4. \u00e7eyrek kazan\u00e7 sonras\u0131 iyimserlik)<\/li>\n<li><strong>Mart 2025<\/strong>: 390-400 $ (genel piyasa d\u00fczeltmesi)<\/li>\n<li><strong>Nisan 2025<\/strong>: 375-385 $ (1. \u00e7eyrek kazan\u00e7 hayal k\u0131r\u0131kl\u0131\u011f\u0131)<\/li>\n<li><strong>May\u0131s 2025<\/strong>: 365-375 $ (sekt\u00f6r genelinde biyoteknoloji sat\u0131\u015flar\u0131)<\/li>\n<li><strong>Haziran 2025<\/strong>: 380-390 $ (\u00fcr\u00fcn hatt\u0131 haberleriyle toparlanma)<\/li>\n<li><strong>Temmuz 2025<\/strong>: 395-405 $ (NHS England ALYFTREK anla\u015fmas\u0131 ile destek)<\/li>\n<li><strong>A\u011fustos 2025<\/strong>: 385-395 $ (mevcut i\u015flem aral\u0131\u011f\u0131)<\/li>\n<\/ul>\n<p>Dalgalanmalara ra\u011fmen, hisse senedi her d\u00fc\u015f\u00fc\u015ften sonra \u00f6nemli bir diren\u00e7 g\u00f6sterdi; yat\u0131r\u0131mc\u0131lar Vertex&#8217;in franchise i\u015finin ve yenilik\u00e7i \u00fcr\u00fcn hatt\u0131n\u0131n temel de\u011ferini fark ediyor.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/tr\/register\/\" class=\"po-cta-green\">Ticarete Ba\u015fla\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2>\n<p><strong>2025 Y\u0131l Sonu Hedefi<\/strong>: 440-460 $<br \/> ALYFTREK benimsenmesi ve Casgevy geni\u015flemesinden kaynaklanan b\u00fcy\u00fcmenin 3. ve 4. \u00e7eyrek kazan\u00e7lar\u0131nda devam etmesi, ayr\u0131ca a\u011fr\u0131 ve diyabet programlar\u0131ndan potansiyel olumlu veriler bekleniyor.<\/p>\n<p><strong>2026 Projeksiyonu<\/strong>: 480-520 $<br \/> ALYFTREK&#8217;in yakla\u015f\u0131k 1 milyar $ sat\u0131\u015fa ula\u015fmas\u0131, Casgevy&#8217;nin potansiyel olarak blockbuster olmas\u0131 (1 milyar $+), ve \u00fcr\u00fcn hatt\u0131ndan yeni lansmanlar.<\/p>\n<p><strong>2028 G\u00f6r\u00fcn\u00fcm\u00fc<\/strong>: 580-650 $<br \/> Opioid olmayan a\u011fr\u0131 tedavilerinin tam ticarile\u015fmesi, tip 1 diyabet tedavi pazar\u0131na giri\u015f ve geni\u015fletilmi\u015f gen terapisi uygulamalar\u0131.<\/p>\n<p><strong>2030 Vizyonu<\/strong>: 700-800 $+<br \/> Genetik t\u0131pta bask\u0131n konum, birden fazla hastal\u0131k i\u00e7in potansiyel k\u00fcratif tedaviler ve \u00e7e\u015fitli terap\u00f6tik alanlarda k\u00fcresel pazar liderli\u011fi.<\/p>\n<p><strong>Karar<\/strong>: Uzun vadeli yat\u0131r\u0131mc\u0131lar i\u00e7in G\u00dc\u00c7L\u00dc ALIM. Mevcut fiyat, birden fazla kataliz\u00f6r\u00fcn ger\u00e7ekle\u015fmesinden \u00f6nce cazip bir giri\u015f noktas\u0131 sunuyor.<\/p>\n<h2>\u26a0\ufe0f Yat\u0131r\u0131m Riskleri ve Olumlu \u0130\u015faretler<\/h2>\n<h3>Dikkate Al\u0131nmas\u0131 Gereken Riskler:<\/h3>\n<ul>\n<li><strong>Patent S\u00fcresi Dolmas\u0131<\/strong>: Ana patentlerin s\u00fcresinin dolmas\u0131na ba\u011fl\u0131 %35 gelir azalmas\u0131 riski<\/li>\n<li><strong>Reg\u00fclasyon Zorluklar\u0131<\/strong>: 250 milyon $&#8217;a kadar potansiyel para cezalar\u0131 ve onay gecikmeleri<\/li>\n<li><strong>Ar-Ge Ba\u015far\u0131s\u0131zl\u0131klar\u0131<\/strong>: Klinik denemelerde ba\u015far\u0131s\u0131zl\u0131k durumunda 500 milyon $+ risk<\/li>\n<li><strong>Yo\u011funla\u015fma Riski<\/strong>: Gelirin %99&#8217;unun kistik fibrozis tedavilerinden gelmesi nedeniyle k\u0131r\u0131lganl\u0131k<\/li>\n<li><strong>Klinik Geri Ad\u0131mlar<\/strong>: Solunan mRNA terapisi \u00fczerindeki son duraklama geli\u015fim risklerini g\u00f6steriyor<\/li>\n<\/ul>\n<h3>2025 \u0130\u00e7in Ye\u015fil I\u015f\u0131klar:<\/h3>\n<ul>\n<li><strong>ALYFTREK Ba\u015far\u0131s\u0131<\/strong>: Temmuz 2025&#8217;te NHS England geri \u00f6deme anla\u015fmas\u0131 sa\u011fland\u0131, eski tedavilere k\u0131yasla %71 etkinlik ile \u00fcst\u00fcn klinik sonu\u00e7lar<\/li>\n<li><strong>Casgevy Patlamas\u0131<\/strong>: 1. \u00e7eyrekte %77,5 ard\u0131\u015f\u0131k b\u00fcy\u00fcme ile 14,2 milyon $ sat\u0131\u015f, blockbuster stat\u00fcs\u00fcne do\u011fru ilerliyor<\/li>\n<li><strong>\u00dcr\u00fcn Hatt\u0131 \u0130lerlemesi<\/strong>: VX-880, Faz III denemelerinde %42 akci\u011fer fonksiyonu iyile\u015fmesi g\u00f6steriyor<\/li>\n<li><strong>Stratejik Sat\u0131n Almalar<\/strong>: 4,9 milyar $ Alpine Immune Sciences sat\u0131n al\u0131m\u0131, b\u00f6brek hastal\u0131klar\u0131 programlar\u0131n\u0131 h\u0131zland\u0131r\u0131yor<\/li>\n<li><strong>Sekt\u00f6r Tan\u0131n\u0131rl\u0131\u011f\u0131<\/strong>: 2025 TIME100 En Etkili \u015eirketler listesine se\u00e7ildi<\/li>\n<\/ul>\n<h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h2>\n<ol>\n<li><strong>K\u00fc\u00e7\u00fck Ba\u015flay\u0131n<\/strong>: Portf\u00f6y\u00fcn\u00fcz\u00fcn %2-5&#8217;ini temsil eden bir pozisyonla ba\u015flay\u0131n\u2014500 $ bile kesirli hisse al\u0131m\u0131 i\u00e7in yeterlidir<\/li>\n<li><strong>Dolar Maliyet Ortalamas\u0131<\/strong>: Dalgalanma s\u0131ras\u0131nda zamanlama hatalar\u0131n\u0131 \u00f6nlemek i\u00e7in ayl\u0131k sabit tutarlarda yat\u0131r\u0131m yap\u0131n<\/li>\n<li><strong>Fiyat Uyar\u0131lar\u0131 Kurun<\/strong>: 3 Kas\u0131m kazan\u00e7lar\u0131 civar\u0131nda potansiyel al\u0131m f\u0131rsatlar\u0131n\u0131 izleyin<\/li>\n<li><strong>Uzun Vadeli D\u00fc\u015f\u00fcn\u00fcn<\/strong>: Bu, 3-5 y\u0131ll\u0131k bir yat\u0131r\u0131m hikayesi, h\u0131zl\u0131 bir i\u015flem de\u011fil<\/li>\n<\/ol>\n<p>Esprili bir yorum: &#8220;VRTX ticareti yapmak, bir CRISPR deneyini izlemek gibidir\u2014k\u0131sa vadede bazen karma\u015f\u0131k, ancak bilim i\u015fe yararsa devrim niteli\u011finde sonu\u00e7lar potansiyeli var!&#8221;<\/p>\n<h2>\u2705 Vertex Pharmaceuticals Incorporated (VRTX) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Ad\u0131m Ad\u0131m<\/h2>\n<table border=\"1\" cellpadding=\"5\" cellspacing=\"0\">\n<thead>\n<tr>\n<th>Ad\u0131m<\/th>\n<th>\u0130\u015flem<\/th>\n<th>Neden \u00d6nemli<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Bir Ticaret Platformu Se\u00e7in<\/td>\n<td>NASDAQ listeleri ve k\u00fc\u00e7\u00fck yat\u0131r\u0131mlar i\u00e7in kesirli hisse sunan platformlar\u0131 tercih edin<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Hesap Fonlamas\u0131n\u0131 Tamamlay\u0131n<\/td>\n<td>Risk almaya haz\u0131r oldu\u011funuz bir miktarla ba\u015flay\u0131n\u2014100 $ bile yeterlidir<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>&#8220;VRTX&#8221; Aramas\u0131 Yap\u0131n<\/td>\n<td>Sadece &#8220;Vertex&#8221; de\u011fil, tam sembol\u00fc kullan\u0131n<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>Emir T\u00fcr\u00fcn\u00fc Se\u00e7in<\/td>\n<td>Giri\u015f fiyat\u0131n\u0131 kontrol etmek i\u00e7in limit emirleri kullan\u0131n; dalgalanma s\u0131ras\u0131nda piyasa emirlerinden ka\u00e7\u0131n\u0131n<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>\u0130nceleyin ve Onaylay\u0131n<\/td>\n<td>Komisyon \u00fccretlerini kontrol edin\u2014i\u015flem de\u011ferinizin %1&#8217;inden az olmas\u0131na dikkat edin<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h3>Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Pocket Option&#8217;\u0131n \u00d6ne \u00c7\u0131kma Nedenleri<\/h3>\n<p>Pocket Option, yeni ba\u015flayanlar i\u00e7in \u00f6zelliklerle hisse senedi yat\u0131r\u0131m\u0131n\u0131 devrim niteli\u011finde de\u011fi\u015ftiriyor:<\/p>\n<ul>\n<li><strong>5 $ Minimum Para Yat\u0131rma<\/strong>: Minimal riskle stratejileri test etmek i\u00e7in ideal<\/li>\n<li><strong>An\u0131nda Do\u011frulama<\/strong>: Tek belge ile KYC, dakikalar i\u00e7inde i\u015flem yapman\u0131z\u0131 sa\u011flar<\/li>\n<li><strong>\u00c7e\u015fitli Para \u00c7ekme Se\u00e7enekleri<\/strong>: Kripto, e-c\u00fczdanlar ve geleneksel bankac\u0131l\u0131k dahil 100&#8217;den fazla y\u00f6ntem<\/li>\n<li><strong>Kesirli Hisseler<\/strong>: VRTX gibi y\u00fcksek fiyatl\u0131 hisselere tam hisse almadan yat\u0131r\u0131m yapma imkan\u0131<\/li>\n<\/ul>\n<h2>\ud83c\udf0d 2025&#8217;te Vertex: Genetik T\u0131bb\u0131n \u00d6nc\u00fcs\u00fc<\/h2>\n<p>Vertex Pharmaceuticals, kistik fibrozis tedavi pazar\u0131nda %90&#8217;dan fazla paya sahip ancak bu sadece ba\u015flang\u0131\u00e7. \u015eirket, CRISPR ortakl\u0131\u011f\u0131 arac\u0131l\u0131\u011f\u0131yla gen d\u00fczenlemeye h\u0131zla geni\u015fliyor, orak h\u00fccre hastal\u0131\u011f\u0131, beta-talasemi ve potansiyel olarak tip 1 diyabet i\u00e7in tedavi geli\u015ftirmekte.<\/p>\n<p>Son <a href=\"https:\/\/www.thepharmaletter.com\/pharmaceutical\/vertex-secures-nhs-deal-for-once-daily-cystic-fibrosis-therapy\">NHS England ALYFTREK anla\u015fmas\u0131<\/a>, yeni nesil tedavilerinin ticari uygulanabilirli\u011fini g\u00f6sterirken, <a href=\"https:\/\/time.com\/collections\/time100-companies-2025\/7289665\/vertex-pharmaceuticals\/\">TIME100 tan\u0131n\u0131rl\u0131\u011f\u0131<\/a> ila\u00e7 geli\u015ftirmedeki yenilik\u00e7i yakla\u015f\u0131mlar\u0131n\u0131 do\u011fruluyor.<\/p>\n<p><strong>\u0130lgin\u00e7 Bilgi<\/strong>: Vertex&#8217;in ara\u015ft\u0131rma tesisinde, bilim insanlar\u0131n\u0131n ba\u015far\u0131s\u0131z deneyleri kutlad\u0131\u011f\u0131 \u00f6zel bir &#8220;ba\u015far\u0131s\u0131zl\u0131k laboratuvar\u0131&#8221; bulunuyor\u2014\u00e7\u00fcnk\u00fc her ba\u015far\u0131s\u0131zl\u0131k, genetik t\u0131pta ger\u00e7ekten i\u015fe yarayan\u0131 anlamalar\u0131na bir ad\u0131m daha yakla\u015ft\u0131r\u0131yor!<\/p>\n"},"faq":[{"question":"Vertex Pharmaceuticals hisseleri nas\u0131l sat\u0131n al\u0131n\u0131r?","answer":"Bir yat\u0131r\u0131m platformu se\u00e7in, hesab\u0131n\u0131z\u0131 fonlay\u0131n, \"VRTX\" sembol\u00fc ile arama yap\u0131n, limit emirleri kullanarak al\u0131m yap\u0131n ve i\u015flemi onaylay\u0131n."},{"question":"Vertex hisseleri i\u00e7in 2025 fiyat hedefi nedir?","answer":"2025 y\u0131l sonu hedefi 440-460 $ aral\u0131\u011f\u0131ndad\u0131r, b\u00fcy\u00fcme kataliz\u00f6rleri ile fiyat\u0131n artmas\u0131 beklenmektedir."},{"question":"Vertex'in en b\u00fcy\u00fck riskleri nelerdir?","answer":"Patent s\u00fcresi dolmas\u0131, reg\u00fclasyon zorluklar\u0131, Ar-Ge ba\u015far\u0131s\u0131zl\u0131klar\u0131 ve klinik geri ad\u0131mlar ba\u015fl\u0131ca risklerdir."},{"question":"Yeni ba\u015flayanlar Vertex hisselerine nas\u0131l yat\u0131r\u0131m yapmal\u0131?","answer":"K\u00fc\u00e7\u00fck ba\u015flay\u0131n, dolar maliyet ortalamas\u0131 yap\u0131n, fiyat uyar\u0131lar\u0131 kurun ve uzun vadeli d\u00fc\u015f\u00fcn\u00fcn."},{"question":"Vertex'in genetik t\u0131p alan\u0131ndaki yenilikleri nelerdir?","answer":"CRISPR terapileri, kistik fibrozis tedavileri ve gen d\u00fczenleme ile orak h\u00fccre hastal\u0131\u011f\u0131, beta-talasemi ve tip 1 diyabet i\u00e7in potansiyel tedaviler geli\u015ftirmektedir."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"Vertex Pharmaceuticals hisseleri nas\u0131l sat\u0131n al\u0131n\u0131r?","answer":"Bir yat\u0131r\u0131m platformu se\u00e7in, hesab\u0131n\u0131z\u0131 fonlay\u0131n, \"VRTX\" sembol\u00fc ile arama yap\u0131n, limit emirleri kullanarak al\u0131m yap\u0131n ve i\u015flemi onaylay\u0131n."},{"question":"Vertex hisseleri i\u00e7in 2025 fiyat hedefi nedir?","answer":"2025 y\u0131l sonu hedefi 440-460 $ aral\u0131\u011f\u0131ndad\u0131r, b\u00fcy\u00fcme kataliz\u00f6rleri ile fiyat\u0131n artmas\u0131 beklenmektedir."},{"question":"Vertex'in en b\u00fcy\u00fck riskleri nelerdir?","answer":"Patent s\u00fcresi dolmas\u0131, reg\u00fclasyon zorluklar\u0131, Ar-Ge ba\u015far\u0131s\u0131zl\u0131klar\u0131 ve klinik geri ad\u0131mlar ba\u015fl\u0131ca risklerdir."},{"question":"Yeni ba\u015flayanlar Vertex hisselerine nas\u0131l yat\u0131r\u0131m yapmal\u0131?","answer":"K\u00fc\u00e7\u00fck ba\u015flay\u0131n, dolar maliyet ortalamas\u0131 yap\u0131n, fiyat uyar\u0131lar\u0131 kurun ve uzun vadeli d\u00fc\u015f\u00fcn\u00fcn."},{"question":"Vertex'in genetik t\u0131p alan\u0131ndaki yenilikleri nelerdir?","answer":"CRISPR terapileri, kistik fibrozis tedavileri ve gen d\u00fczenleme ile orak h\u00fccre hastal\u0131\u011f\u0131, beta-talasemi ve tip 1 diyabet i\u00e7in potansiyel tedaviler geli\u015ftirmektedir."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Vertex Pharmaceuticals Incorporated (VRTX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Vertex Pharmaceuticals Incorporated (VRTX) Hisse Senedi Yat\u0131r\u0131m\u0131<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-vertex-pharmaceuticals-incorporated\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Vertex Pharmaceuticals Incorporated (VRTX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Vertex Pharmaceuticals Incorporated (VRTX) Hisse Senedi Yat\u0131r\u0131m\u0131\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-vertex-pharmaceuticals-incorporated\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-19T15:42:59+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Yazan:\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-vertex-pharmaceuticals-incorporated\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-vertex-pharmaceuticals-incorporated\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"Vertex Pharmaceuticals Incorporated (VRTX) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Vertex Pharmaceuticals Incorporated (VRTX) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"datePublished\":\"2025-08-19T15:42:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-vertex-pharmaceuticals-incorporated\/\"},\"wordCount\":21,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-vertex-pharmaceuticals-incorporated\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals16.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-vertex-pharmaceuticals-incorporated\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-vertex-pharmaceuticals-incorporated\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-vertex-pharmaceuticals-incorporated\/\",\"name\":\"Vertex Pharmaceuticals Incorporated (VRTX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Vertex Pharmaceuticals Incorporated (VRTX) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-vertex-pharmaceuticals-incorporated\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-vertex-pharmaceuticals-incorporated\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals16.webp\",\"datePublished\":\"2025-08-19T15:42:59+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-vertex-pharmaceuticals-incorporated\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-vertex-pharmaceuticals-incorporated\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-vertex-pharmaceuticals-incorporated\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals16.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals16.webp\",\"width\":1408,\"height\":768},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-vertex-pharmaceuticals-incorporated\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/tr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Vertex Pharmaceuticals Incorporated (VRTX) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Vertex Pharmaceuticals Incorporated (VRTX) Hisse Senedi Yat\u0131r\u0131m\u0131\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"tr\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Vertex Pharmaceuticals Incorporated (VRTX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Vertex Pharmaceuticals Incorporated (VRTX) Hisse Senedi Yat\u0131r\u0131m\u0131","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-vertex-pharmaceuticals-incorporated\/","og_locale":"tr_TR","og_type":"article","og_title":"Vertex Pharmaceuticals Incorporated (VRTX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Vertex Pharmaceuticals Incorporated (VRTX) Hisse Senedi Yat\u0131r\u0131m\u0131","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-vertex-pharmaceuticals-incorporated\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-19T15:42:59+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Yazan:":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-vertex-pharmaceuticals-incorporated\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-vertex-pharmaceuticals-incorporated\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"Vertex Pharmaceuticals Incorporated (VRTX) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Vertex Pharmaceuticals Incorporated (VRTX) Hisse Senedi Yat\u0131r\u0131m\u0131","datePublished":"2025-08-19T15:42:59+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-vertex-pharmaceuticals-incorporated\/"},"wordCount":21,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-vertex-pharmaceuticals-incorporated\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals16.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"tr","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-vertex-pharmaceuticals-incorporated\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-vertex-pharmaceuticals-incorporated\/","url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-vertex-pharmaceuticals-incorporated\/","name":"Vertex Pharmaceuticals Incorporated (VRTX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Vertex Pharmaceuticals Incorporated (VRTX) Hisse Senedi Yat\u0131r\u0131m\u0131","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-vertex-pharmaceuticals-incorporated\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-vertex-pharmaceuticals-incorporated\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals16.webp","datePublished":"2025-08-19T15:42:59+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-vertex-pharmaceuticals-incorporated\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-vertex-pharmaceuticals-incorporated\/"]}]},{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-vertex-pharmaceuticals-incorporated\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals16.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals16.webp","width":1408,"height":768},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-vertex-pharmaceuticals-incorporated\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/tr\/"},{"@type":"ListItem","position":2,"name":"Vertex Pharmaceuticals Incorporated (VRTX) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Vertex Pharmaceuticals Incorporated (VRTX) Hisse Senedi Yat\u0131r\u0131m\u0131"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/tr\/#website","url":"https:\/\/pocketoption.com\/blog\/tr\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"tr"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"tr_TR","wpml_translations":{"vt_VT":{"locale":"vt_VT","id":338629,"slug":"how-to-buy-vertex-pharmaceuticals-incorporated","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Vertex Pharmaceuticals Incorporated (VRTX) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Vertex Pharmaceuticals Incorporated (VRTX)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-vertex-pharmaceuticals-incorporated\/"},"pt_AA":{"locale":"pt_AA","id":338637,"slug":"how-to-buy-vertex-pharmaceuticals-incorporated","post_title":"Como comprar a\u00e7\u00f5es da Vertex Pharmaceuticals Incorporated (VRTX) - Investimento em a\u00e7\u00f5es da Vertex Pharmaceuticals Incorporated (VRTX)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-vertex-pharmaceuticals-incorporated\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/338631","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/comments?post=338631"}],"version-history":[{"count":1,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/338631\/revisions"}],"predecessor-version":[{"id":338634,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/338631\/revisions\/338634"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media\/334126"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media?parent=338631"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/categories?post=338631"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/tags?post=338631"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}